Clinical Trials Logo

Acute Bleeding Esophageal Varices clinical trials

View clinical trials related to Acute Bleeding Esophageal Varices.

Filter by:
  • None
  • Page 1

NCT ID: NCT01851564 Completed - Clinical trials for Acute Bleeding Esophageal Varices

RCT of Stent Versus Standard Therapy in Oesophageal Variceal Haemorrhage

SOV
Start date: August 2012
Phase: N/A
Study type: Interventional

The mortality rates from Acute Variceal Haemorrhage remain significant and first line therapy may fail in 15-25% of patients. The self-expandable metal stent has been described in case series as having a very high efficacy at control of haemorrhage from oesophageal varices when used as rescue therapy. This randomised controlled trial aims to assess for any potential superiority of the stent over 'standard' endoscopic techniques as primary or rescue therapy for bleeding oesophageal varices.

NCT ID: NCT01618890 Recruiting - Liver Cirrhosis Clinical Trials

Hepatic Venous Pressure Gradient-guided Versus Standard Beta-blocker Therapy in Primary Prevention of Variceal Bleeding

Porthos
Start date: September 2012
Phase: Phase 3
Study type: Interventional

Study hypothesis: Hepatic venous pressure gradient (HVPG)-directed primary prophylaxis with nonselective beta-blocker therapy (NSBB) leads to a reduction in first variceal bleeding episodes and is cost-effective in the long term. Study design: A multi-center randomized controlled study comparing nonselective beta-blocker therapy guided by the hemodynamic response as determined by the difference in HVPG before and after starting oral NSBB therapy, to standard heart rate-guided NSBB therapy in patients with esophageal varices due to liver cirrhosis without a history of esophageal variceal hemorrhage. Primary study parameters/outcome of the study: First variceal bleeding episodes occurring within the first two years. Secondary study parameters/outcome of the study: - Mortality - Occurrence of other cirrhosis-related complications - Occurrence of hepatocellular carcinoma - Costs of treatments - Adverse effects

NCT ID: NCT01267669 Completed - Cirrhosis Clinical Trials

A Trial of Somatostatin With Endoscopic Variceal Ligation (EVL) in Control of Acute Variceal Bleeding

AVB-EVL+S
Start date: November 2005
Phase: N/A
Study type: Interventional

Background: Efficacy of endoscopic variceal sclerotherapy in achieving initial control of acute variceal bleeding and five-day haemostasis has been shown to significantly improve when vasoactive drug is added. However, there is limited data whether addition of somatostatin, to endoscopic variceal ligation (EVL) improves the efficacy of EVL. Aim: To compare EVL plus somatostatin versus EVL plus placebo in control of acute variceal bleeding. Patients and methods: Consecutive cirrhotic patients with acute variceal bleeding from esophageal varices were enrolled in the trial. After emergency EVL, patients were randomized to receive either somatostatin (250 mcg/hr) or placebo infusion. Primary endpoint was treatment failure within 5 days. Treatment failure was defined as fresh hematemesis ≥2 hour after start of therapy or death.